No Data
No Data
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced
Replimune | 10-K: Annual report
Express News | Replimune Group Inc. Expects Enrollment Of First Patients In Phase 3 Confirmatory Trial Of RP1 In Advanced Melanoma In 2H 2024
Express News | Replimune Group Inc -Enrollment of First Patients in Phase 3 Confirmatory Trial of Rp1 in Advanced Melanoma Expected in 2H 2024
Replimune Group FY24 Loss/Shr $3.24 >REPL
Replimune Group FY24 Loss/Shr $3.24 >REPL
Express News | Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
No Data